文献类型：期刊文献

中文题名：中医药治疗良性前列腺增生症的基础与临床研究进展

英文题名：Research progress of traditional Chinese medicine in treatment of benign prostatic hyperplasia

作者：李生龙[1];卢刚刚[1];金广炜[1];殷鹏东[1];龚美胜[2];李慧[1];马旭[1];李喜香[3];赵渊博[1];田大成[1];梁永林[4];赵永强[5]

第一作者：李生龙

机构：[1]甘肃中医药大学中西医结合学院,甘肃兰州730000;[2]黑龙江省中医药科学院研究生院,黑龙江哈尔滨150006;[3]甘肃省中医院药学部,甘肃兰州730050;[4]甘肃中医药大学基础医学院,甘肃兰州730000;[5]甘肃省中医院泌尿外科,甘肃兰州730050

第一机构：甘肃中医药大学中西医结合学院

年份：2024

卷号：49

期号：21

起止页码：5817

中文期刊名：中国中药杂志

外文期刊名：China Journal of Chinese Materia Medica

收录：CSTPCD;;Scopus;北大核心:【北大核心2023】；CSCD:【CSCD2023_2024】；PubMed;

基金：国家中医药管理局科技司2023年中央财政转移支付地方项目(甘财社[2023]53号);甘肃省科学技术厅重点研发项目(22YF7FA101);国家社会科学基金项目(18XMZ031)。

语种：中文

中文关键词：良性前列腺增生症;中医药;基础研究;临床研究;综述

外文关键词：benign prostatic hyperplasia;traditional Chinese medicine;basic research;clinical research;review

摘要：良性前列腺增生症(benign prostatic hyperplasia,BPH)是一种以下尿路症状为主要表现的中老年男性常见病,严重影响患者生活质量。其发病机制尚未完全明确,且目前西医在BPH治疗中仍存在一些挑战和局限性。因此,寻找新的更有效的治疗策略迫在眉睫。近年来,诸多基础及临床研究证实,中医药在BPH治疗中的重要作用已备受瞩目。该文通过综述中医药治疗BPH的基础及临床研究进展,认为基础研究主要围绕中药活性成分[调控核转录因子E2相关因子2(Nrf2)/抗氧化反应元件(ARE)、核因子κB(NF-κB)、表皮生长因子受体(EGFR)/信号传导及转录激活蛋白3(STAT3)、磷脂酰肌醇3-激酶(PI3K)/蛋白激酶B(Akt)/哺乳动物雷帕霉素靶蛋白(mTOR)、p38丝裂原活化蛋白激酶(p38 MAPK)/叉形头转录因子的O亚型(FOXO3a)等通路]、单味中药(调节促炎因子、细胞增殖因子氧化相关蛋白、细胞周期相关蛋白及促凋亡因子等表达)、中药复方与中成药[调控细胞外调节蛋白激酶(ERK1/2)、转化生长因子-β(TGF-β)/Smad、丝裂原活化蛋白激酶(MAPK)、PI3K/Akt、Nrf2、解痉多肽2(TFF2)/Wnt、白细胞介素-6(IL-6)/Janus激酶2(JAK2)/STAT3、低氧诱导因子1α(HIF-1α)/血管内皮细胞生长因子受体(VEGFR)等通路]展开,进而通过抑制BPH细胞增殖、氧化应激、炎症反应,促进凋亡,抗上皮间充质转化等途径起到治疗作用。临床研究多以内治、外治、内外合治及中西医结合治疗为主要手段,通过改善中医证候积分、前列腺症状评分、残余尿量、有效膀胱容积、性生活质量、平均尿流率、最大尿流率,促进性激素分泌平衡等途径起治疗作用。通过该研究,以期为BPH的临床研究和药物研发提供一定的参考与思路。
Benign prostatic hyperplasia(BPH)is a common disease in middle-aged and elderly men,with lower urinary tract symptoms as the main manifestation,severely affecting the quality of life of patients.The pathogenesis of BPH is not yet fully understood,and there are still some challenges and limitations in western medicine treatment for BPH.Therefore,finding new and more effective treatment strategies is urgent.In recent years,many basic and clinical studies have confirmed the important role of traditional Chinese medicine in the treatment of BPH.This article reviews the progress of basic and clinical research in the treatment of BPH with traditional Chinese medicine,and believes that basic research mainly focuses on the active ingredients of Chinese medicine[regulating pathways such as NF-E2-related factor 2(Nrf2)/antioxidant response element(ARE),nuclear factorκB(NF-κB),epidermal growth factor receptor(EGFR)/signal transducer and activator of transcription 3(STAT3),phosphoinositide 3-kinase(PI3K)/protein kinase B(Akt)/mammalian target of rapamycin(mTOR),p38 mitogen-activated protein kinase(p38 MAPK)/forkhead box O subtype(FOXO3a),etc.],single Chinese herbs(regulating inflammatory factors,oxidative stress-related proteins,cell cycle-related proteins,and apoptotic factors,etc.),and Chinese herbal compounds and patent medicines[regulating extracellular signal-regulated kinase(ERK1/2),transforming growth factor-β(TGF-β)/Smad,mitogen-activated protein kinase(MAPK),PI3K/Akt,Nrf2,trefoil factor 2(TFF2)/Wnt,interleukin-6(IL-6)/Janus kinase 2(JAK2)/STAT3,hypoxia-inducible factor 1α(HIF-1α)/vascular endothelial growth factor receptor(VEGFR),etc.],and then play a therapeutic role by inhibiting BPH cell proliferation,oxidative stress,inflammatory response,promoting apoptosis,and inhibiting epithelial-mesenchymal transition.Clinical studies mainly focus on internal treatment,external treatment,combined internal and external treatment,and integrated Chinese and western medicine treatment as the main methods,aiming to improve traditional Chinese medicine syndrome scores,prostate symptom scores,residual urine volume,effective bladder volume,sexual quality of life,increase average urine flow rate,maximum urine flow rate,and promote balance of sex hormone secretion.Through this research,it is hoped to provide some reference ideas for clinical research and drug development for BPH.